Compare EVF & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVF | RANI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 106.9M |
| IPO Year | 1998 | 2021 |
| Metric | EVF | RANI |
|---|---|---|
| Price | $4.96 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 49.3K | ★ 670.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $4.85 | $0.44 |
| 52 Week High | $5.60 | $3.87 |
| Indicator | EVF | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 55.38 |
| Support Level | $4.93 | $0.86 |
| Resistance Level | $5.04 | $0.94 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 30.25 | 64.50 |
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.